Acorda Therapeutics, Inc. Restructuring Charges
Acorda Therapeutics, Inc. reported Restructuring Charges of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-04-01
- Acorda Therapeutics, Inc. restructuring charges for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Acorda Therapeutics, Inc. restructuring charges for the quarter ending 2022-12-31 was -$49.00K, a 103.50% decline year-over-year.
- Acorda Therapeutics, Inc. restructuring charges for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Acorda Therapeutics, Inc. restructuring charges for the quarter ending 2022-06-30 was $25.00K, a 7.41% decline year-over-year.
- Acorda Therapeutics, Inc. restructuring charges for fiscal 2022 was $251.00K, a 95.82% decline from fiscal 2021.
- Acorda Therapeutics, Inc. restructuring charges for fiscal 2021 was $6.00M, a 1649.27% increase from fiscal 2020.
- Acorda Therapeutics, Inc. restructuring charges for fiscal 2020 was $343.00K, a 92.21% decline from fiscal 2019.
- Acorda Therapeutics, Inc. restructuring charges for fiscal 2019 was $4.40M, a 234.42% increase from fiscal 2018.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | -$49.00K derived: sum of 2 quarters · filed 2024-04-01 | -$49.00K derived: sum of 3 quarters · filed 2024-04-01 | -$24.00K derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-12-31 | -$49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$49.00K derived: sum of 2 quarters · filed 2024-04-01 | -$24.00K derived: sum of 3 quarters · filed 2024-04-01 | $251.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $25.00K derived: sum of 2 quarters · filed 2022-11-14 | $300.00K 10-Q · filed 2022-11-14 | $1.65M derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-06-30 | $25.00K 10-Q · filed 2022-11-14 | $300.00K 10-Q · filed 2022-08-09 | $1.65M derived: sum of 3 quarters · filed 2023-03-15 | $4.08M derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-03-31 | $226.00K 10-Q · filed 2022-11-14 | $1.63M derived: sum of 2 quarters · filed 2023-03-15 | $4.06M derived: sum of 3 quarters · filed 2023-03-15 | $4.08M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $3.83M derived: sum of 2 quarters · filed 2023-03-15 | $3.86M derived: sum of 3 quarters · filed 2023-03-15 | $6.00M 10-K · filed 2023-03-15 |
| 2021-09-30 | $2.43M 10-Q · filed 2021-11-12 | $2.46M derived: sum of 2 quarters · filed 2021-11-12 | $4.60M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $27.00K 10-Q · filed 2021-11-12 | $2.20M 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $2.12M 10-Q · filed 2021-11-12 | |||
| 2020-12-31 | $343.00K 10-K · filed 2022-03-18 | |||
| 2019-12-31 | $4.40M 10-K · filed 2020-02-28 | $4.40M 10-K · filed 2021-03-16 | ||
| 2018-12-31 | $1.32M 10-K · filed 2020-02-28 | |||
| 2017-12-31 | $22.00K 10-K/A · filed 2018-03-09 | $56.00K derived: sum of 2 quarters · filed 2018-03-09 | $7.65M derived: sum of 3 quarters · filed 2018-03-09 | $7.65M 10-K · filed 2019-02-27 |
| 2017-09-30 | $34.00K 10-K/A · filed 2018-03-09 | $7.62M derived: sum of 2 quarters · filed 2018-03-09 | ||
| 2017-06-30 | $7.59M 10-K/A · filed 2018-03-09 | $7.59M 10-Q · filed 2017-08-08 |